Item request has been placed! ×
Item request cannot be made. ×
loading  Processing Request

Association between the triglyceride-glucose index and in-hospital major adverse cardiovascular events in patients with acute coronary syndrome: results from the Improving Care for Cardiovascular Disease in China (CCC)-Acute Coronary Syndrome project.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
  • المؤلفون: Wang W;Wang W; Yang J; Yang J; Wang K; Wang K; Niu J; Niu J; Liu Y; Liu Y; Ge H; Ge H
  • المصدر:
    Cardiovascular diabetology [Cardiovasc Diabetol] 2024 May 15; Vol. 23 (1), pp. 170. Date of Electronic Publication: 2024 May 15.
  • نوع النشر :
    Journal Article; Observational Study; Multicenter Study
  • اللغة:
    English
  • معلومة اضافية
    • Corporate Authors:
    • المصدر:
      Publisher: BioMed Central Country of Publication: England NLM ID: 101147637 Publication Model: Electronic Cited Medium: Internet ISSN: 1475-2840 (Electronic) Linking ISSN: 14752840 NLM ISO Abbreviation: Cardiovasc Diabetol Subsets: MEDLINE
    • بيانات النشر:
      Original Publication: London : BioMed Central, [2002-
    • الموضوع:
    • نبذة مختصرة :
      Objective: Although the TyG index is a reliable predictor of insulin resistance (IR) and cardiovascular disease, its effectiveness in predicting major adverse cardiac events in hospitalized acute coronary syndrome (ACS) patients has not been validated in large-scale studies. In this study, we aimed to explore the association between the TyG index and the occurrence of MACEs during hospitalization.
      Methods: We recruited ACS patients from the CCC-ACS (Improving Cardiovascular Care in China-ACS) database and calculated the TyG index using the formula ln(fasting triglyceride [mg/dL] × fasting glucose [mg/dL]/2). These patients were classified into four groups based on quartiles of the TyG index. The primary endpoint was the occurrence of MACEs during hospitalization, encompassing all-cause mortality, cardiac arrest, myocardial infarction (MI), and stroke. We performed Cox proportional hazards regression analysis to clarify the correlation between the TyG index and the risk of in-hospital MACEs among patients diagnosed with ACS. Additionally, we explored this relationship across various subgroups.
      Results: A total of 101,113 patients were ultimately included, and 2759 in-hospital MACEs were recorded, with 1554 (49.1%) cases of all-cause mortality, 601 (21.8%) cases of cardiac arrest, 251 (9.1%) cases of MI, and 353 (12.8%) cases of stroke. After adjusting for confounders, patients in TyG index quartile groups 3 and 4 showed increased risks of in-hospital MACEs compared to those in quartile group 1 [HR = 1.253, 95% CI 1.121-1.400 and HR = 1.604, 95% CI 1.437-1.791, respectively; p value for trend < 0.001], especially in patients with STEMI or renal insufficiency. Moreover, we found interactions between the TyG index and age, sex, diabetes status, renal insufficiency status, and previous PCI (all p values for interactions < 0.05).
      Conclusions: In patients with ACS, the TyG index was an independent predictor of in-hospital MACEs. Special vigilance should be exercised in females, elderly individuals, and patients with renal insufficiency.
      (© 2024. The Author(s).)
    • References:
      Am Heart J. 2016 Sep;179:107-15. (PMID: 27595685)
      Eur J Prev Cardiol. 2022 Aug 22;29(11):1531-1541. (PMID: 35512245)
      Cardiovasc Diabetol. 2022 Jul 1;21(1):123. (PMID: 35778734)
      Cardiovasc Diabetol. 2021 Oct 13;20(1):206. (PMID: 34645432)
      Circ Res. 2016 Apr 1;118(7):1151-69. (PMID: 27034277)
      J Am Coll Cardiol. 2003 Apr 16;41(8):1387-93. (PMID: 12706936)
      Nat Rev Cardiol. 2023 Nov;20(11):778-788. (PMID: 37231077)
      Cardiovasc Diabetol. 2022 May 6;21(1):68. (PMID: 35524263)
      Cardiovasc Diabetol. 2020 Jul 8;19(1):109. (PMID: 32641042)
      Cardiovasc Diabetol. 2021 Jan 12;20(1):19. (PMID: 33435964)
      Cardiovasc Diabetol. 2020 Sep 29;19(1):155. (PMID: 32993633)
      Metabolism. 2021 Dec;125:154892. (PMID: 34563556)
      Int Urol Nephrol. 2023 May;55(5):1279-1289. (PMID: 36472799)
      Curr Diab Rep. 2018 Jun 8;18(7):44. (PMID: 29884917)
      JAMA Cardiol. 2021 Apr 1;6(4):437-447. (PMID: 33471027)
      J Am Soc Nephrol. 2006 Oct;17(10):2937-44. (PMID: 16988059)
      Cardiovasc Diabetol. 2022 Sep 16;21(1):187. (PMID: 36114495)
      Cardiovasc Diabetol. 2022 Nov 3;21(1):229. (PMID: 36329456)
      J Diabetes Complications. 2018 Apr;32(4):418-423. (PMID: 29449137)
      Front Endocrinol (Lausanne). 2021 Nov 05;12:761397. (PMID: 34803922)
      BMC Med Inform Decis Mak. 2019 Apr 9;19(Suppl 2):61. (PMID: 30961585)
      PLoS One. 2021 Jun 18;16(6):e0252855. (PMID: 34143812)
      Arch Endocrinol Metab. 2023 Mar 30;67(3):378-384. (PMID: 37011373)
      Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3024-3030. (PMID: 34625361)
      Diabetes Care. 2008 Aug;31(8):1590-5. (PMID: 18487475)
      J Hum Hypertens. 2015 Apr;29(4):260-7. (PMID: 25355008)
      Cardiovasc Diabetol. 2022 Nov 24;21(1):256. (PMID: 36434636)
      JAMA. 2022 Feb 15;327(7):662-675. (PMID: 35166796)
      Front Cardiovasc Med. 2021 May 31;8:644035. (PMID: 34136539)
      Am J Physiol Endocrinol Metab. 2008 Jan;294(1):E15-26. (PMID: 17957034)
      Cardiovasc Diabetol. 2020 Jun 13;19(1):80. (PMID: 32534586)
      Front Endocrinol (Lausanne). 2023 Apr 20;14:1150980. (PMID: 37152938)
      Diabetologia. 2015 May;58(5):886-99. (PMID: 25725623)
      Prev Med. 2016 May;86:99-105. (PMID: 26854766)
    • Grant Information:
      81973841 National Natural Science Foundation of China
    • الموضوع:
      Date Created: 20240515 Date Completed: 20240516 Latest Revision: 20240613
    • الموضوع:
      20240614
    • الرقم المعرف:
      PMC11097581
    • الرقم المعرف:
      10.1186/s12933-024-02270-7
    • الرقم المعرف:
      38750553